UC San Diego cancer researchers receive NCI Outstanding Investigator Award

August 28, 2015

Four University of California, San Diego School of Medicine researchers have been selected to receive the newly established National Cancer Institute (NCI) Outstanding Investigator Award. The multi-million dollar awards fund new projects that have an unusual potential in cancer research over seven years.

The recipients are Kun-Liang Guan, PhD, Distinguished Professor in the Department of Pharmacology, who will receive $5.9 million for his work with mTORC1 and Hippo pathways in cell growth and cancer; Tannishtha Reya, PhD, professor in the Department of Pharmacology and Medicine, who was awarded $6.3 million for her project on molecular strategies for early detection and targeting of cancer; and Jin Zhang, PhD, professor in the Department of Pharmacology, who will receive $6.5 million to evaluate live-cell activity architecture in cancer. The funding amount for Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology, is pending. Karin is studying the role of immunosuppressive B cells in the development of cancer and its treatment.

"Cancer research is moving at an accelerated pace but there are still many unanswered questions that our team is trying to answer through innovative science," said Scott Lippman, MD, director of Moores Cancer Center at UC San Diego Health. "The NCI Outstanding Investigator Award provides important additional resources that will help us realize scientific discoveries best accomplished at a comprehensive cancer center."

NCI anticipates funding approximately 60 Outstanding Investigator Awards. The grant program was developed to provide researchers with substantial time and resources to break new ground or extend previous discoveries that advance biomedical, behavioral or clinical cancer research.

"We are exceptionally pleased that the National Cancer Institute has recognized the outstanding talent of our faculty," said Joan Heller Brown, PhD, Department of Pharmacology chair. "The Outstanding Investigator Award will allow them to focus on developing new ideas and research directions based on their proven track records, without the major interruption incurred through writing and revising grant applications every few years. Our department has continued to grow in strength in the area of cancer biology and is dedicated to making basic discoveries that will inform the quest for new cancer therapeutics."

Research summaries:

Guan, a member of Moores Cancer Center, studies the basic mechanisms of cell growth regulation and how alteration of mTORC1 and Hippo pathways control cell growth and tissue/organ homeostasis. mTORC1 is a central cell growth controller which promotes cell growth by stimulating biosynthesis and inhibiting autophagy. The goal is to develop enabling technologies to probe the active molecules in their native environment and characterize how these active molecules change in cancer.

Reya, also a member of Moores Cancer Center, focuses on understanding the mechanisms by which cancers subvert normal developmental and stem cell signals to grow, spread and evade therapy. Over the last decade her work has ranged from the discovery of new signals involved in cancer growth and progression to preclinical work that has formed the basis of clinical trials testing new agents for drug-resistant leukemias.

Zhang, a member of Moores Cancer Center, is developing enabling technologies to probe active molecules in their native environment and characterize how they change in cancer. This research may lead to new ways of studying dysregulated molecular machinery in cancer, thereby better guiding therapeutic interventions that target the dysregulation.

Karin, a member of Moores Cancer Center and the National Academy of Sciences, has been studying the role of pre-existing and tumor-elicited inflammation in cancer development, malignant progression and response to therapy. His work has laid the foundation of the burgeoning inflammation and cancer field and helped establish the critical role played by innate and adaptive immune cells and the cytokines they produce in the pathogenesis of cancer and its treatment.

University of California - San Diego

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.